169 related articles for article (PubMed ID: 35676062)
1. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.
Wang X; Muzaffar J; Kirtane K; Song F; Johnson M; Schell MJ; Li J; Yoder SJ; Conejo-Garcia JR; Guevara-Patino JA; Bonomi M; Bhateja P; Rocco JW; Steuer CE; Saba NF; Chung CH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35676062
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
Ge H; Ferris RL; Wang JH
Clin Cancer Res; 2023 Feb; 29(3):647-658. PubMed ID: 36315045
[TBL] [Abstract][Full Text] [Related]
3. Low Pretreatment CD4
Turner RJ; Guy TV; Geraghty NJ; Splitt A; Watson D; Brungs D; Carolan MG; Miller AA; de Leon JF; Aghmesheh M; Sluyter R
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628721
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.
Poropatich K; Fontanarosa J; Swaminathan S; Dittmann D; Chen S; Samant S; Zhang B
J Pathol; 2017 Nov; 243(3):354-365. PubMed ID: 28771750
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
6. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
8. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
[TBL] [Abstract][Full Text] [Related]
9. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response.
Kansy BA; Shayan G; Jie HB; Gibson SP; Lei YL; Brandau S; Lang S; Schmitt NC; Ding F; Lin Y; Ferris RL
Oncoimmunology; 2018; 7(11):e1494112. PubMed ID: 30377562
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
[TBL] [Abstract][Full Text] [Related]
11. The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients.
Khunger A; Rytlewski JA; Fields P; Yusko EC; Tarhini AA
Oncoimmunology; 2019; 8(11):e1652538. PubMed ID: 31646098
[TBL] [Abstract][Full Text] [Related]
12. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH; Li J; Steuer CE; Bhateja P; Johnson M; Masannat J; Poole MI; Song F; Hernandez-Prera JC; Molina H; Wenig BM; Kumar S; Kuperwasser C; Stephens PJ; Farinhas JM; Shin DM; Kish JA; Muzaffar J; Kirtane K; Rocco JW; Schell MJ; Saba NF; Bonomi M
Clin Cancer Res; 2022 Jun; 28(11):2329-2338. PubMed ID: 35344035
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
15. Real-world Data Study of the Efficacy and Toxicity of Nivolumab
Macia-Rivas L; Fernandez-Laguna CL; Alvarez-Asteinza C; Maray I; Carbajales-Alvarez M; Lozano-Blazquez A
Anticancer Res; 2023 Apr; 43(4):1681-1688. PubMed ID: 36974777
[TBL] [Abstract][Full Text] [Related]
16. Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
Glazar DJ; Johnson M; Farinhas J; Steuer CE; Saba NF; Bonomi M; Chung CH; Enderling H
Oral Oncol; 2022 Apr; 127():105787. PubMed ID: 35248922
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Luginbuhl AJ; Johnson JM; Harshyne LA; Linnenbach AJ; Shukla SK; Alnemri A; Kumar G; Cognetti DM; Curry JM; Kotlov N; Antysheva Z; Degryse S; Mannion K; Gibson MK; Netterville J; Brown B; Axelrod R; Zinner R; Tuluc M; Gargano S; Leiby BE; Shimada A; Mahoney MG; Martinez-Outschoorn U; Rodeck U; Kim YJ; South AP; Argiris A
Clin Cancer Res; 2022 Mar; 28(5):915-927. PubMed ID: 34911681
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals TCR
Jiang Y; Zhang S; Tang L; Li R; Zhai J; Luo S; Peng Y; Chen X; Wei L
Front Immunol; 2022; 13():1030222. PubMed ID: 36389736
[TBL] [Abstract][Full Text] [Related]
19. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
[TBL] [Abstract][Full Text] [Related]
20. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
